Anteris Technologies Ltd operates as a structural heart company.
Anteris Technologies Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$8.70|
|52 Week High||AU$3.41|
|52 Week Low||AU$13.75|
|1 Month Change||4.07%|
|3 Month Change||3.20%|
|1 Year Change||115.35%|
|3 Year Change||n/a|
|5 Year Change||-78.78%|
|Change since IPO||-88.55%|
Recent News & Updates
Increases to CEO Compensation Might Be Put On Hold For Now at Anteris Technologies Ltd (ASX:AVR)
Shareholders of Anteris Technologies Ltd ( ASX:AVR ) will have been dismayed by the negative share price return over...
|AVR||AU Medical Equipment||AU Market|
Return vs Industry: AVR exceeded the Australian Medical Equipment industry which returned -8.2% over the past year.
Return vs Market: AVR exceeded the Australian Market which returned 17.9% over the past year.
Stable Share Price: AVR is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: AVR's weekly volatility (6%) has been stable over the past year.
About the Company
Anteris Technologies Ltd operates as a structural heart company. The company offers ADAPT technology, which re-engineers xenograft tissue into a pure collagen scaffold; and develops DurAVRTM, a 3D single piece aortic valve for the treatment of aortic stenosis. It also researches and develops regenerative medicine and immunotherapies.
Anteris Technologies Fundamentals Summary
|AVR fundamental statistics|
Is AVR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AVR income statement (TTM)|
|Cost of Revenue||AU$1.83m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-2.44|
|Net Profit Margin||-311.96%|
How did AVR perform over the long term?See historical performance and comparison
Is Anteris Technologies undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Anteris Technologies is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Anteris Technologies has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
How is Anteris Technologies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Anteris Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Anteris Technologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AVR is currently unprofitable.
Growing Profit Margin: AVR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AVR is unprofitable, but has reduced losses over the past 5 years at a rate of 10.6% per year.
Accelerating Growth: Unable to compare AVR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AVR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).
Return on Equity
High ROE: AVR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Anteris Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: AVR has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: AVR has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: AVR has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: AVR's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AVR has sufficient cash runway for 3 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: AVR is forecast to have sufficient cash runway for 5 months based on free cash flow estimates, but has since raised additional capital.
What is Anteris Technologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AVR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AVR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AVR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AVR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AVR's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Wayne Paterson (54 yo)
Mr. Wayne G. Paterson is the Founder and Chief Executive Officer of ProCom Rx since June 2013. Mr. Paterson has been Chief Executive Officer of Anteris Technologies Ltd (formerly known as Admedus Limited)...
CEO Compensation Analysis
Compensation vs Market: Wayne's total compensation ($USD1.32M) is above average for companies of similar size in the Australian market ($USD300.22K).
Compensation vs Earnings: Wayne's compensation has been consistent with company performance over the past year.
Experienced Management: AVR's management team is considered experienced (3.6 years average tenure).
Experienced Board: AVR's board of directors are considered experienced (3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 36.4%.
Anteris Technologies Ltd's employee growth, exchange listings and data sources
- Name: Anteris Technologies Ltd
- Ticker: AVR
- Exchange: ASX
- Founded: 1999
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: AU$70.130m
- Shares outstanding: 8.06m
- Website: https://www.anteristech.com
- Anteris Technologies Ltd
- Toowong Tower
- Suite 302
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/14 15:44|
|End of Day Share Price||2021/10/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.